Novozymes and Neugenesis join forces in pharmaceutical proteins  

A new production method could lead to more cost efficiently produced monoclonal antibodies.

Novozymes and US-based Neugenesis have joined forces to develop a new production method for antibodies. The research project combines Novozymes’ core competencies in gene technology with Neugenesis’ patented technology in monoclonal antibodies. Novozymes says that the initiative forms part of its strategy to enter into areas outside the enzyme business such as pharmaceutical proteins. If successful, the new production method will be an important step in developing a faster and more economic method for producing monoclonal antibodies, which are used for treating diseases such as breast cancer and respiratory infections. The news is reported in financial newspaper Børsen today.


Neugenesis Corporation is a privately held biotechnology company which has leveraged its fundamental research employing the filamentous fungus, Neurospora crassa, into commercial biotechnology applications. Novozymes A/S is a biotech-based world leader in enzymes and microorganisms for industrial use. Headquartered in Denmark, Novozymes is represented in 25 countries and sells enzymes and microorganisms in more than 130 countries. The company employs more than 3,500 people.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×